Tests ABS-1230 in children and young adults with KCNT1-related epilepsy
Tests ABS-1230 against placebo in young people with KCNT1-related epilepsy.
Plain-language title generated from the registry record
Registry title: A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of ABS-1230 in Pediatric and Young Adult Participants With KCNT1-related Epilepsy
Key facts
- Where
- Hackensack and Rochester, United StatesSee the 2 sites
- Phase
- Phase 2
Where in United States
- Northeast Regional Epilepsy GroupHackensack, United StatesTaking people
- University of Rochester Medical CenterRochester, United StatesNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Actio Biosciences, Inc.
- Trial code
- NCT07600736
- Record updated
- 15 October 2026
- Original description
This trial will evaluate the safety, tolerability, pharmacokinetics, and clinical activity of ABS-1230 compared with placebo in participants with KCNT1-related epilepsyRead full original descriptionShow less
A Phase 1b/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of ABS-1230 Administered to Pediatric and Young Adult Participants With KCNT1-Related Epilepsy
This trial will evaluate the safety, tolerability, pharmacokinetics, and clinical activity of ABS-1230 compared with placebo in participants with KCNT1-related epilepsy
Inclusion: Aged 1 month to <22 years; Clinician-confirmed diagnosis of KCNT1-related epilepsy; Has an average of at least 4 countable motor seizures per week; Is taking no more than 6 antiseizure medications (ASM) and is able to keep stable doses of ASMs for the duration of Part 1 or Part 2.
Exclusion: Is currently taking phenytoin, carbamazepine, stiripentol, or quinidine; Has a medical condition that, in the opinion of the investigator, would limit the participant's ability to participate in the study or might compromise participant safety or interfere with evaluation of the study drug.